Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 + SBRT in Oligometastatic ESCC
NCT05626569Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoint: 1-year progression-free survival. Started Dec 2022; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05626569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626569.